Phase 2 N=47 DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury
Brain Injuries · Craniocerebral Trauma · Trauma, Nervous System
Primary: Ventilator-free Days — 16.2; 18.05 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=643 ELITE: Early Versus Late Intervention Trial With Estradiol
Atherosclerosis
Primary: Progression of Subclinical Atherosclerosis — 0.0044; 0.0078; 0.0100; 0.0088 mm per year
Phase 2 N=41 Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Verbal Short Term Memory — 43.7; 37.9; 43.6; 40.8 t-score — p=0.90
Phase 2 N=1,011 Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Infections, Meningococcal
Primary: Number of Subjects With Vaccine Response to Serum Bactericidal Assay Using Human Complement Against Neisseria Meningitidis Serogroup A, C, W-135 and Y (hSBA-MenA…
Phase 2 N=65 Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery
Breast Cancer
Primary: Number of Participants With Grade 3+ Treatment-related Skin, Fibrosis, and Breast Pain Adverse Events — 1 participants
Phase 2 N=10 Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Absolute Change in Right Ventricular Ejection Fraction — 10.4 % RVEF — p=0.028
Phase 2 N=104 Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma
Asthma
Primary: Percentage of Participants With Asthma Exacerbation — 44.2; 5.8; 19.2; 1.9 percentage of participants — p=<0.0001
Phase 2 N=6 Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
Recurrent Non-small Cell Lung Cancer · Squamous Cell Lung Cancer · Stage III Non-small Cell Lung Cancer
Primary: 6-month Progression Free Survival (PFS) Rate Within the Entire FGFR1 Amplified Group — 0 percentage of participants
Phase 2 N=88 Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients
Liver Transplant Recipients · Liver Transplantation · Immunosuppression
Primary: Number of Operationally Tolerant Participants — 33 Participants
Phase 2 N=73 Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis
Cystic Fibrosis
Primary: Change in Sputum Myeloperoxidase (MPO) Level — -0.10; 0.03 log10 (ng/mL) — p=0.460
Phase 2 N=500 Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study
Clostridium Difficile
Primary: Seroconversion Rate (SCR) on Day 56 — 71.5; 83.0; 59.6; 0.0 percentage of study participants — p=<0.0001
Phase 2 N=136 Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
Immunosuppresion · Thrombocytopenia · Pancytopenia
Primary: Hematologic Response — 38; 20; 3 Participants
Phase 2 N=103 PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: FEV1 AUC0-12 — 1.477; 1.497; 1.443; 1.514 Liter
Phase 2 N=63 N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis
Schizophrenic Psychoses
Primary: Change in Negative Symptoms of Schizophrenia as Measured on the PANSS — 16.9; 17.2 units on a scale — p=0.50
Phase 2 N=175 Prothrombotic Inflammatory Markers in Women With Metabolic Syndrome - Effect of Atorvastatin
Metabolic Syndrome
Primary: Mean Low Density Lipoprotein Cholesterol in Blood — 70; 135 mg/dl